EMVision Medical Devices Says Recruitment for Brain Scanner Validation Trial Surpasses 200 Patients
MT Newswires Live
8 hours ago
EMVision Medical Devices (ASX:EMV) said recruitment for its pivotal validation trial for its point-of-care emu brain scanning device surpassed 200 patients across the training and primary analysis groups, according to a Monday Australian bourse filing.
The emu device was incorporated into "code stroke" workflows at participating hospitals, and no device-related adverse events had been reported to date, the company said. The company is also adding additional US academic medical centers to the trial, expanding recruitment capacity.
The primary objective of the trial is to demonstrate hemorrhage detection sensitivity and specificity of greater than 80%.
The medical device company's shares added about 2% in recent Monday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.